Making GLP-1 agonists and related drugs (ozempic, mounjaro) cheaply/widely available seems like it would be excellent public policy.
back
1 comments
It seems that they also make you lose tons of lean mass. Normal diets you lose 25% of the lost weight in lean, these seem more like 40%.
https://peterattiamd.com/the-downside-of-glp-1-receptor-agon...
“Lean mass loss was 2.6% versus 10.9%. Those on tirzepatide had about a threefold greater reduction in fat mass than lean mass, resulting in an overall improvement in body composition. Fat mass as a proportion of overall body mass decreased from 46.8% to 44.7% with placebo, compared with 46.2% to 38.5% with tirzepatide. Similarly, lean mass as a proportion of body mass increased from 50.7% to 52.4% with placebo, compared with 51.0% to 58.1% with tirzepatide. Fat-to-lean mass ratio improved more with tirzepatide than placebo, with greater improvements observed in patients who lost more body weight.”
https://www.practiceupdate.com/content/easd-2022-substantial....
Yea, their overall composition still improved of course, because they lost more than 50% in fat. But they lost more lean mass than people who lose that weight in other ways, is my understanding.
In an apples to apples study it showed similar effects to canagliflozin which works through an entirely different pathway. So it's probably not related to GLP-1 but to the speed and effectiveness of weightloss which will most likely be faster than a typical diet.